PO-0809: MRS Choline/NAA enhancement is a predictor of post-RT disease-free survival time in glioblastoma multiforme  by Rowland, B. et al.
S406                                                                                                                                         3rd ESTRO Forum 2015 
 
September 2011, and with Carbon ion beam in 2012. 
Skullbase chordomas are known as radioresistant tumors. 
Escalating the dose to target volumes and sparing normal 
organs is recommended to ensure adequate local control with 
low toxicity.  
Materials and Methods: Since September 2011, 67 patients ( 
F/M : 25/42) with histologically verified diagnosis of skullbase 
chordomas have been treated at CNAO. All patients 
underwent first one or more surgical procedures, and then 
were irradiated on macroscopic residual disease or on the 
site of local relapse ( 2 patients had local relapse after 
complete resection). Thirty nine patients have been treated 
with proton beam, up to a total dose of 74 GyE in 37 
fractions, 2 GyE/fraction over 5 days per week, twenty eight 
patients with carbon ion up to70.4 GyE in 16 fractions, 4.4 
GyE/fraction over 4 days per week. Each patient underwent 
clinical examination during, at the end and every three 
months after the treatment. Acute and late toxicity data 
were recorded according to CTCAE v.4.0 score. Clinical 
outcome was evaluated with trimestral MRI according to 
RECIST criteria. 
Results: Treatment has been in general well tolerated, with 
acute toxicity G0/G1, G2 and G3 reported respectively in 
74%, 24% and 2% patients; one patient died for causes not 
treatment related. 
With 15 months median follow up time ( range 2 – 27), local 
control was achieved in 51 patients (over the 54 who reached 
the first follow up visit), partial response in 2, and complete 
response in 1. No progression disease has been reported. In 
the 34 patients who reached 12 months follow up, 26 patients 
were scored with late toxicity G0/G1 (alopecia, fatigue, 
dysphagia, headache, hearing loss), and 8 patients with G2 
(pituitary deficit, neuropathy, asymptomatic brain 
dysfuncion). 
Conclusions: Our data show safety and effectiveness of 
handrontherapy for skullbase chordomas although the limited 
number of patients and the short follow up time. Longer 
follow up are needed. 
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Purpose/Objective: In brain 1H Magnetic Resonance 
Spectroscopic Imaging (MRSI) elevated choline and reduced 
NAcetylAspartate (NAA) levels are both indicators of 
cancerous tissue and the Choline/NAA Ratio (CNR) is a widely 
studied parameter for evaluating tumor metabolic function. 
In this study we compare CNRs in healthy tissue and tumor 
across a cohort of GlioBlastoma Multiforme (GBM) patients 
and investigate the link between spectroscopic abnormality 
and disease-free survival after treatment. 
Materials and Methods: 14 patients diagnosed with GBM 
underwent an MRSI exam as part of the (post-operative) 
radiotherapy treatment planning imaging process. The scan 
was a PRESS localized CSI with 10x10x8 voxels of 
approximately 0.5cc, TE/TR=135ms/1.5s. Data was 
processed, quantified, registered to the coacquired T1 
contrast enhanced scan and resampled to the T1 resolution 
using a custom tool developed in-house. After treatment, 
every patient received follow up MRIs every 1-2 months until 
relapse. 
Amongst GBM patients a GTV to CTV margin of 20mm is 
typically used to account for microscopic spread. Voxels 
greater than 20mm outside the CTV contour were classified 
as 'normal' and for each patient a Gaussian distribution was 
fitted to the CNRs of these voxels to obtain a mean normal 
CNR. As the CNRs in the contrast enhanced region do not 
typically form a Gaussian distribution, the median value was 
utilised. The Choline/NAA Enhancement (CNE) was defined as 
the ratio between median tumour CNR and mean normal 
CNR. 
Results: The normal tissue CNR across the group was 0.84 +/- 
0.10, showing a wide range of healthy tissue values across 
patients. Four patients exhibited no voxels with 
spectroscopic abnormalities. The mean CNE was 1.73 +/- 
0.65. 
Patients were divided into two groups (equal in number) 
based on the mean CNE and disease-free survival curves for 
both were constructed using the Kaplan-Meier estimator, 
shown in the figure, then compared using the log rank test, 
which showed a significant difference (p=0.00645) between 
the two groups.  
 
 
Conclusions: Our study found the baseline levels of 
metabolites to vary substantially between patients 
(attributable at least in part to tumor location), so that an 
absolute threshold for abnormal CNR cannot be determined 
for all patients. Instead we proposed a measure of relative 
abnormality, CNE, which can be compared across patients. 
There is a statistically significant relationship between our 
CNE and the disease-free survival of our patient cohort. Thus 
this study demonstrates that spectroscopic analysis of the 
CNE could help guide treatment planning by indicating 
patients who might benefit from more radical radiotherapy 
options such as dose boosting. The metric could also be used 
to tailor patient follow-up in order to more closely monitor 
patients with high risk of early relapse. 
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